Evidence based medicine
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction . RCT - placebo control trial . https://www.nejm.org/doi/full/10.1056/NEJMoa1911303. P- Total 4744 patients with HFref . 2373- Dapagliflozin 10mg od . 2371 - placebo I- Dapagliflozin vs placebo C- Placebo O - The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. 1) 237 - In dapaglifozin grp had worsening heart failure and 227- Died. 2) 326- placebo had worsening HF 273- DIED . CONCLUSION : Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. But pts who were included , dapagliflozon had more patients with NYHA class 2 and placebo had more pts with NYHA class 3,4 HF .